Evidence map›Paper›PMID 36237224›Full record

ArticleJournal of the Saudi Heart Association2022

Saudi Heart Association Position Statement on the Use of Biomarkers for the Management of Heart Failure and Acute Coronary Syndrome.

Waleed AlHabeeb, Adel Abdulkader Tash, Fawaz Almutari, Kamal Al Ghalayini, Maryam Alqaseer, Mostafa Alshamiri, Suleiman Kharabsheh, Wail AlKashkari

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Saudi Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Elevated ASGR1 as a Potential Diagnostic Biomarker for Coronary Artery Disease and Predictor of Adverse Outcomes in Hypertensive Patients.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Four new markers of early thrombotic molecules and thromboelastography in prognostic evaluation of AMI patients undergoing PCI.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Waleed AlHabeebDepartment of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia.
Adel Abdulkader TashAdult Cardiac Surgery, Ministry of Health, Jeddah, Saudi Arabia.
Fawaz AlmutariCardiac Sciences, King Abdulaziz Cardiac Center, Ministry of National Guard, Riyadh, Saudi Arabia.
Kamal Al GhalayiniKing Abdulaziz University, Jeddah, Saudi Arabia.
Maryam AlqaseerDepartment of Heart Failure, King Fahad Specialist Hospital Dammam, Saudi Arabia.
Mostafa AlshamiriCardiac Sciences, King Saud University, Riyadh, Saudi Arabia.
Suleiman KharabshehTelemetry and Cardiac Holding Unit, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Wail AlKashkariDepartment of Congenital and Structural Intervention, National Guard Hospital, Jeddah, Saudi Arabia.
King Saud University · SAKing Abdulaziz University · SAKing Fahad Specialist Hospital · SAKing Faisal Specialist Hospital & Research Centre · SAMinistry of Health · SANational Guard Health Affairs · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The burden of acute coronary syndrome (ACS) and heart failure (HF) remains high in Saudi Arabia. Biomarkers can greatly improve the management and outcomes of these conditions, but no official guidance is available on their use in Saudi Arabia. Consensus panel: An expert panel of cardiologists, interventional cardiologists and cardiac surgeon reviewed available evidence and formulated recommendations relevant to clinical practice in Saudi Arabia. Consensus findings: high-sensitivity cardiac troponins play a major role in the diagnosis of ACS and the exclusion of myocardial infarction in patients with HF. Natriuretic Peptides are recommended to determine the likelihood of a diagnosis of HF in a chronic setting and rapidly exclude HF in an acute setting. High-sensitivity cardiac troponins and NT-proBNP have good prognostic ability in ACS and HF. These biomarkers could also facilitate discharge planning and reduce unnecessary hospital admissions and resource wastage. The use of biomarkers should not be excessive and should abide by appropriateness criteria. High-sensitivity assays and NT-proBNP measurements are preferred. Conclusion: By outlining expert recommendations on the best practices in the use of biomarkers, the panel hopes to contribute towards a recognized updated guidance for all healthcare providers in Saudi Arabia on the evidence-based management of HF and ACS.

Indexed as

Acute coronary syndromeBiomarkersHeart failureManagementSaudi Arabia

Identifiers

PMID36237224
PMCPMC9518724
OpenAlexW4292544706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.